Skip to main content
SpringerLink
Log in

Tocilizumab ± methotrexate not a cost-effective option in early RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The U-Act trial and the U-Act-After study were funded by Roche Nederland BV.

Reference

  • Verhoeven MMA, et al. Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation. The Journal of Rheumatology : Aug 2020. Available from: URL: http://doi.org/10.3899/jrheum.200067

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tocilizumab ± methotrexate not a cost-effective option in early RA. PharmacoEcon Outcomes News 860, 33 (2020). https://doi.org/10.1007/s40274-020-7079-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7079-8

Search

Navigation